COVID-19 and Fungal infections: a double debacle
Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID...
Gespeichert in:
| Veröffentlicht in: | Microbes and infection 2022-11, Vol.24 (8), p.105039, Article 105039 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 105039 |
| container_title | Microbes and infection |
| container_volume | 24 |
| creator | Mina, Sara Yaakoub, Hajar Annweiler, Cédric Dubée, Vincent Papon, Nicolas |
| description | Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species. |
| doi_str_mv | 10.1016/j.micinf.2022.105039 |
| format | Article |
| fullrecord | <record><control><sourceid>hal_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9400371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1286457922001095</els_id><sourcerecordid>oai_HAL_inserm_03762881v1</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-3ee5c067570cc51e9373d1d7c5748a4d947a5f60c5c57a214c9dde427b486df83</originalsourceid><addsrcrecordid>eNp9kM9KAzEQh4MotlbfwMM-gFuTbP5sPAhSrS0UelHxFrLJbJuymy3ZtuDbu2VF0YOnGWZ-8zF8CF0TPCaYiNvNuPbWh3JMMaXdiONMnaAhkUKlkrD3066nuUgZl2qALtp2gzHhUrBzNMgEzjCmbIjwZPk2f0yJSkxwyXQfVqZKOirYnW9Ce5eYxDX7ooLEQWFsBZforDRVC1dfdYRep08vk1m6WD7PJw-L1DIpd2kGwC0WkktsLSegMpk54qTlkuWGOcWk4aXAlncTQwmzyjlgVBYsF67MsxG677nbfVGDsxB20VR6G31t4odujNe_N8Gv9ao5aMUwziTpADc9YP3nbPaw0D60EGvdBQXNc3I4xlkft7Fp2wjl9w3B-ihcb3QvXB-F6174z5vQuTh4iLq1HoIF52PnULvG_w_4BDtPh9w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>COVID-19 and Fungal infections: a double debacle</title><source>Elsevier ScienceDirect Journals</source><creator>Mina, Sara ; Yaakoub, Hajar ; Annweiler, Cédric ; Dubée, Vincent ; Papon, Nicolas</creator><creatorcontrib>Mina, Sara ; Yaakoub, Hajar ; Annweiler, Cédric ; Dubée, Vincent ; Papon, Nicolas</creatorcontrib><description>Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species.</description><identifier>ISSN: 1286-4579</identifier><identifier>EISSN: 1769-714X</identifier><identifier>DOI: 10.1016/j.micinf.2022.105039</identifier><identifier>PMID: 36030024</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Aspergillus ; Candida ; COVID-19 ; Fungal infections ; Life Sciences ; Mucoromycetes ; Pneumocystis ; Review</subject><ispartof>Microbes and infection, 2022-11, Vol.24 (8), p.105039, Article 105039</ispartof><rights>2022 Institut Pasteur</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2022 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. 2022 Institut Pasteur</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-3ee5c067570cc51e9373d1d7c5748a4d947a5f60c5c57a214c9dde427b486df83</citedby><cites>FETCH-LOGICAL-c477t-3ee5c067570cc51e9373d1d7c5748a4d947a5f60c5c57a214c9dde427b486df83</cites><orcidid>0000-0003-3555-4559 ; 0000-0001-6265-7321 ; 0000-0001-8467-6021 ; 0000-0002-7199-8109</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1286457922001095$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://inserm.hal.science/inserm-03762881$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Mina, Sara</creatorcontrib><creatorcontrib>Yaakoub, Hajar</creatorcontrib><creatorcontrib>Annweiler, Cédric</creatorcontrib><creatorcontrib>Dubée, Vincent</creatorcontrib><creatorcontrib>Papon, Nicolas</creatorcontrib><title>COVID-19 and Fungal infections: a double debacle</title><title>Microbes and infection</title><description>Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species.</description><subject>Aspergillus</subject><subject>Candida</subject><subject>COVID-19</subject><subject>Fungal infections</subject><subject>Life Sciences</subject><subject>Mucoromycetes</subject><subject>Pneumocystis</subject><subject>Review</subject><issn>1286-4579</issn><issn>1769-714X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kM9KAzEQh4MotlbfwMM-gFuTbP5sPAhSrS0UelHxFrLJbJuymy3ZtuDbu2VF0YOnGWZ-8zF8CF0TPCaYiNvNuPbWh3JMMaXdiONMnaAhkUKlkrD3066nuUgZl2qALtp2gzHhUrBzNMgEzjCmbIjwZPk2f0yJSkxwyXQfVqZKOirYnW9Ce5eYxDX7ooLEQWFsBZforDRVC1dfdYRep08vk1m6WD7PJw-L1DIpd2kGwC0WkktsLSegMpk54qTlkuWGOcWk4aXAlncTQwmzyjlgVBYsF67MsxG677nbfVGDsxB20VR6G31t4odujNe_N8Gv9ao5aMUwziTpADc9YP3nbPaw0D60EGvdBQXNc3I4xlkft7Fp2wjl9w3B-ihcb3QvXB-F6174z5vQuTh4iLq1HoIF52PnULvG_w_4BDtPh9w</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Mina, Sara</creator><creator>Yaakoub, Hajar</creator><creator>Annweiler, Cédric</creator><creator>Dubée, Vincent</creator><creator>Papon, Nicolas</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><general>Institut Pasteur. Published by Elsevier Masson SAS</general><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3555-4559</orcidid><orcidid>https://orcid.org/0000-0001-6265-7321</orcidid><orcidid>https://orcid.org/0000-0001-8467-6021</orcidid><orcidid>https://orcid.org/0000-0002-7199-8109</orcidid></search><sort><creationdate>20221101</creationdate><title>COVID-19 and Fungal infections: a double debacle</title><author>Mina, Sara ; Yaakoub, Hajar ; Annweiler, Cédric ; Dubée, Vincent ; Papon, Nicolas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-3ee5c067570cc51e9373d1d7c5748a4d947a5f60c5c57a214c9dde427b486df83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aspergillus</topic><topic>Candida</topic><topic>COVID-19</topic><topic>Fungal infections</topic><topic>Life Sciences</topic><topic>Mucoromycetes</topic><topic>Pneumocystis</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mina, Sara</creatorcontrib><creatorcontrib>Yaakoub, Hajar</creatorcontrib><creatorcontrib>Annweiler, Cédric</creatorcontrib><creatorcontrib>Dubée, Vincent</creatorcontrib><creatorcontrib>Papon, Nicolas</creatorcontrib><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Microbes and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mina, Sara</au><au>Yaakoub, Hajar</au><au>Annweiler, Cédric</au><au>Dubée, Vincent</au><au>Papon, Nicolas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 and Fungal infections: a double debacle</atitle><jtitle>Microbes and infection</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>24</volume><issue>8</issue><spage>105039</spage><pages>105039-</pages><artnum>105039</artnum><issn>1286-4579</issn><eissn>1769-714X</eissn><abstract>Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species.</abstract><pub>Elsevier Masson SAS</pub><pmid>36030024</pmid><doi>10.1016/j.micinf.2022.105039</doi><orcidid>https://orcid.org/0000-0003-3555-4559</orcidid><orcidid>https://orcid.org/0000-0001-6265-7321</orcidid><orcidid>https://orcid.org/0000-0001-8467-6021</orcidid><orcidid>https://orcid.org/0000-0002-7199-8109</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1286-4579 |
| ispartof | Microbes and infection, 2022-11, Vol.24 (8), p.105039, Article 105039 |
| issn | 1286-4579 1769-714X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9400371 |
| source | Elsevier ScienceDirect Journals |
| subjects | Aspergillus Candida COVID-19 Fungal infections Life Sciences Mucoromycetes Pneumocystis Review |
| title | COVID-19 and Fungal infections: a double debacle |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A21%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20and%20Fungal%20infections:%20a%20double%20debacle&rft.jtitle=Microbes%20and%20infection&rft.au=Mina,%20Sara&rft.date=2022-11-01&rft.volume=24&rft.issue=8&rft.spage=105039&rft.pages=105039-&rft.artnum=105039&rft.issn=1286-4579&rft.eissn=1769-714X&rft_id=info:doi/10.1016/j.micinf.2022.105039&rft_dat=%3Chal_pubme%3Eoai_HAL_inserm_03762881v1%3C/hal_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36030024&rft_els_id=S1286457922001095&rfr_iscdi=true |